Timothy Noyes, president and CEO of Proteon, said: “The issuance of this patent further strengthens and broadens Proteon’s elastase vasodilation franchise. With this patent in hand, Proteon Therapeutics can continue the global development of PRT-201, our lead drug candidate.”